Article
Pan-RAF inhibitor exarafenib targets BRAF class II/III NSCLC and reveals ARAF-KSR1 resistance and combination strategies.
Nature communications - 7 Feb 2026
Manabe Tadashi, Bergo Hannah C, Li Qingtian, Wang Tim Sen, Severson Paul, Miller Nichol, Lee Catherine, Yay Donderici Elifnur, Zhang Nicole, Wu Wei, Chou Yu-Ting, Kerr Daniel L, Allegakoen Paul, Grandinetti Kathryn B, Soroceanu Liliana, Pelham Robert J, Martin Eric S, Murphy Eric A, Khanna Vishesh, Neal Joel W, Chen Christopher T, Kato Shumei, Williams Richard, Bivona Trever G
Abstract excerpt
Oncogenic BRAF mutations, including those in non-small cell lung cancer (NSCLC), are classified as Class I, II, or III. While approved therapies exist for BRAF Class I mutants, no approved therapies exist for Class II and III BRAF-mutated NSCLC. Analysis of a circulating tumor DNA database reveals Class II and III mutations comprise ~65% of BRAF-mutant NSCLC cases, with Class II patients showing worse outcomes...
Topics
- Proto-Oncogene Proteins B-raf
- Humans
- Carcinoma, Non-Small-Cell Lung
- Lung Neoplasms
- Drug Resistance, Neoplasm
- Animals
- Protein Kinase Inhibitors
- Cell Line, Tumor